Φορτώνει......
Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
Itolizumab is a first-in-class anti-CD6 monoclonal antibody that was initially developed for various cancers and was later developed and approved in India for treatment of moderate to severe chronic plaque psoriasis in 2013. This drug is now being re-purposed for COVID-19. The potential utility of i...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | BioDrugs |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer International Publishing
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7551520/ https://ncbi.nlm.nih.gov/pubmed/33048300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-020-00448-5 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|